Sandoz receives European Commission approval for biosimilar Hyrimoz (adalimumab)

Biosimilar Hyrimoz (adalimumab) approved for use in all same indications as reference medicine ** * including rheumatology, gastroenterology and dermatology. Early therapeutic intervention is essential in rheumatoid arthritis, supporting urgency of treatments like Hyrimoz Fourth Sandoz biosimilar approved in Europe** in past 18 months, and seventh in total, underscoring Sandoz commitment to making access happen through a robust portfolio Holzkirchen, July 27, 2018 - Sandoz, a Novartis division and the pioneer and global leader in biosimilars, today announced that the European Commission (EC) granted marketing authorization to biosimilar Hyrimoz (adalimumab) for use in all indications of the reference medicine^***, including rheumatoid arthritis, plaque psoriasis, Crohn's disease, uveitis and ulcerative colitis. Rheumatoid arthritis alone affects up to 1% of people in the European Union. Patients with moderate to severe rheumatoid arthritis can have chronic inflammation that causes fatigue, pain and joint stiffness. Symptoms can be reversible with appropriate treatment, however the joint damage and the resulting disability are permanent. The introduction of biosimilars has been shown to improve access to advanced treatment options, such as biologic medicines. "We believe in making access happen for patients who are suffering from chronic inflammatory diseases.